CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Abionyx Pharma SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Abionyx Pharma SA
Bat. D 33-43 Avenue Georges Pompidou
Phone: +33 562249706p:+33 562249706 BALMA, 31130  France Ticker: ABNXABNX
Business Summary
Abionyx Pharma SA, formerly known as Cerenis Therapeutics Holding SA, is a France-based multinational biopharmaceutical company primarily engaged in the research, development and commercialization of High-density Lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The Company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2022Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board EmmanuelHuynh 54 12/9/2019 12/9/2019
Chief Executive Officer, Executive Director CyrilleTupin 47 6/9/2019 6/9/2019
Chief Financial Officer Emmanuel P.De Fougeroux 1/1/2021
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Lypro Biosciences, Inc. QB3@953 Innovation Center San Francisco CA United States

Business Names
Business Name
ABNX
CEREN
Cerenis Therapeutics
LYPRO BIOSCIENCES

General Information
Number of Employees: 63 (As of 12/31/2022)
Outstanding Shares: 28,185,454 (As of 6/30/2023)
Stock Exchange: EPA
Fax Number: +33 562190417
Email Address: info@cerenis.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024